<DOC>
	<DOCNO>NCT00205283</DOCNO>
	<brief_summary>The purpose study assess impact prospective drug level monitor dose-adjustment nelfinavir ( NFV ) clinical virologic outcome group HIV-infected patient achieve virologic success receive nelfinavir contain highly active antiretroviral therapy ( HAART ) regimen .</brief_summary>
	<brief_title>Nelfinavir M8 Drug-level Monitoring HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Antiretroviral naive currently take nelfinavir contain HAART regimen nelfinavir first protease inhibitor Patients willing comply protocol Age great equal 18 year Virologically successful already establish regimen Prior use protease inhibitor exclusive nelfinavir Required use concomitant use drug may interact contraindicated nelfinavir Use immunomodulators vaccine HIV disease Intercurrent illness time enrollment , clinician 's judgement , could influence HIV RNA concentration Baseline ALT level great five time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HIV</keyword>
</DOC>